Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis (Serum Autoimmune Screen, End-organ Function Tests, Blood Tests, Others), Treatment (Medication, Hormone Replacement Therapy, Others), Dosage Form (Tablet, Capsule, Others), Route of Administration (Oral, Others), Age of Onset (Childhood, Adult, Adolescent), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
The autoimmune polyglandular syndromes (APS) are a group of endocrine abnormalities that appear in distinct patterns in people who have immunological dysregulation, allowing for therapy and prediction of systemic or other hormone deficits. APS1, APS2, and APS3 are the three major entities identified; the unusual X-linked syndrome of polyendocrinopathy, immunodysregulation and enteropathy caused by mutations in the FOXP3 gene also qualifies as an APS. APS-1 treatment is currently focused on the individual symptoms that each patient manifests. Replacement medication for any deficient endocrine hormones and patient education regarding the signs and symptoms of these deficits are critical to treatment effectiveness.
Data Bridge Market Research analyses that the autoimmune polyglandular syndrome type 1 market was valued at USD 228 million in 2021 and is expected to reach USD 347.26 million by 2029, registering a CAGR of 5.40% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnosis (Serum Autoimmune Screen, End-organ Function Tests, Blood Tests, Others), Treatment (Medication, Hormone Replacement Therapy, Others), Dosage Form (Tablet, Capsule, Others), Route of Administration (Oral, Others), Age of Onset (Childhood, Adult, Adolescent), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Zydus Cadila (India), Lupin (India), Amneal Pharmaceuticals LLC. (U.S.), Cipla Inc. (U.S.), Aurobindo Pharma (India), Glenmark Pharmaceuticals Limited (India), Eli Lilly and Company (U.S.), Sun Pharmaceutical Industries Ltd. (India), Allergan (Ireland), Bristol-Myers Squibb Company (U.S.), Takeda Pharmaceutical Company Limited (Japan), Abbott (U.S.). LEO Pharma A/S (Denmark)
|
|
Market Opportunities
|
|
Market Definition
Autoimmune polyglandular syndrome type 1 (APS-1) is a rare and complex recessively inherited immune-cell malfunction illness characterized by several autoimmunities. It manifests as a set of symptoms that include potentially fatal endocrine and gastrointestinal dysfunctions. Autoimmune polyglandular syndrome type 1 (APS1) is a life-threatening disease for which there is no cure. Replacement of hormone deficits caused by autoimmune destruction of several endocrine organs is now the only therapy option.
Autoimmune Polyglandular Syndrome Type 1 Market Dynamics
Drivers
- Rise in the number of cases of autoimmune polyglandular syndrome type 1
The surging number of cases of autoimmune polyglandular syndrome type 1 is a major factor driving the market's growth rate during the forecast period of 2022-2029. Type 1 Autoimmune Polyglandular Syndrome (APS) is a rare inherited condition that affects the body's organs. AIRE gene mutation causes this disease entity. Hypoparathyroidism, Addison's disease, and chronic mucocutaneous candidiasis are the three characteristic clinical symptoms.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of autoimmune polyglandular syndrome type 1 market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising government initiatives to spread awareness about rare diseases and growing level of disposable income will result in the expansion of autoimmune polyglandular syndrome type 1 market. Along with this, favourable reimbursement policies and rising demand for disease-specific treatment will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the autoimmune polyglandular syndrome type 1 market growth.
Moreover, the market's growth is fueled by rising technological advancement in diagnostic methods and emerging new markets. These factors will provide beneficial opportunities for the autoimmune polyglandular syndrome type 1 market growth.
Restraints/Challenges
On the other hand, the high cost associated with the treatment and diagnosis will obstruct the growth rate of the market. Developing economies' lack of healthcare infrastructure and dearth of skilled professionals will challenge the autoimmune polyglandular syndrome type 1 market. Additionally, lack of awareness among people and unfavourable healthcare policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This autoimmune polyglandular syndrome type 1 market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the autoimmune polyglandular syndrome type 1 market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
An uncommon disease, autoimmune polyglandular syndrome type 1, affects 1 in every 2 to 3 million babies. The prevalence is 1 in 90000 in Norway and 1 in 130000 in Ireland, however, it is more frequent in Sardinians and Iranian Jews, with prevalence rates of 1 in 14000 and 1 in 9000, respectively. There is no discernible gender disparity. The age at which the first manifestation occurs varies from 0.2 to 18 years.
Autoimmune polyglandular syndrome type 1 market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Global Autoimmune Polyglandular Syndrome Type 1 Market Scope
The autoimmune polyglandular syndrome type 1 market is segmented on the basis of diagnosis, treatment, dosage form, route of administration, age of onset, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- Serum Autoimmune Screen
- End-organ Function Tests
- Blood Tests
- Others
Treatment
- Medication
- Antifungal Agents
- Fluconazole
- Itraconazole
- Calcitriol
- Corticosteroids
- Hormone Replacement Therapy
- Others
Dosage Form
- Tablet
- Capsule
- Others
Route of Administration
- Oral
- Others
Age of Onset
- Childhood
- Adult
- Adolescent
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Autoimmune Polyglandular Syndrome Type 1 Market Regional Analysis/Insights
The autoimmune polyglandular syndrome type 1 market is analysed and market size insights and trends are provided by country, diagnosis, treatment, dosage form, route of administration, age of onset, end-users and distribution channel as referenced above.
The countries covered in the autoimmune polyglandular syndrome type 1 market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the autoimmune polyglandular syndrome type 1 market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing prevalence of autoimmune polyglandular syndrome type 1 and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, growing presence of major key players will further propel the market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to development of healthcare infrastructure in this region. Also, rising government initiatives will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Autoimmune Polyglandular Syndrome Type 1 Market Share Analysis
The autoimmune polyglandular syndrome type 1 market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to autoimmune polyglandular syndrome type 1 market.
Some of the major players operating in the autoimmune polyglandular syndrome type 1 market are:
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Zydus Cadila (India)
- Lupin (India)
- Amneal Pharmaceuticals LLC. (U.S.)
- Cipla Inc. (U.S.)
- Aurobindo Pharma (India)
- Glenmark Pharmaceuticals Limited (India)
- Eli Lilly and Company (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Allergan (Ireland)
- Bristol-Myers Squibb Company (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Abbott (U.S.)
- LEO Pharma A/S (Denmark)
SKU-